Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + docetaxel + cisplatin + 5-fluorouracil
- Development stage
- Phase 3
- Lead developer
- InnoKeys
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of nimotuzumab, a humanized IgG1 monoclonal antibody, and the TPF chemotherapy regimen, which includes docetaxel, cisplatin, and 5-fluorouracil. Nimotuzumab targets the extracellular domain of the epidermal growth factor receptor (EGFR), blocking ligand binding and inhibiting downstream signaling pathways involved in tumor cell proliferation, survival, and angiogenesis. The TPF components provide multi-targeted cytotoxic activity: docetaxel stabilizes microtubules to induce cell cycle arrest, cisplatin creates DNA cross-links that trigger apoptosis, and 5-fluorouracil inhibits thymidylate synthase to impair DNA replication. This specific regimen was evaluated in a Phase 2 clinical trial (NCT01425736) led by Wei Guo at Shanghai Ninth People's Hospital for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
- Brand names
- Adrucil
- Other names
- Nimotuzumab + TPFNimotuzumab + Docetaxel + Cisplatin + 5-FU
02
Targets
DNAEGFR (Epidermal growth factor receptor)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nimotuzumab + docetaxel + cisplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + docetaxel + cisplatin + 5-fluorouracil.